Inventiva SA ADR (IVA) has released an update.
Inventiva’s recent publication in Nature Communications reveals that its drug lanifibranor shows significant improvement in cardiometabolic health markers for MASH/NASH patients. The NATIVE Phase IIb clinical trial data indicates that lanifibranor not only aids in managing insulin resistance, lipid metabolism, and systemic inflammation but also prevents the progression of prediabetes in patients. These promising results highlight lanifibranor’s potential as a holistic treatment option for MASH/NASH, a disease associated with increased cardiovascular risk.
For further insights into IVA stock, check out TipRanks’ Stock Analysis page.
